{"title":"Pharmacogenomics of Antihypertensive Drugs","authors":"Yashi Dixit, Amit Joshi, Manali Singh","doi":"10.5185/amp.2022.010429","DOIUrl":null,"url":null,"abstract":"These drugs are commonly used but, in some cases, they may become harmful for the person who is going through this medication so in this case pharmacogenomics of antihypertensive drugs are used. There are a variety of useful medication adherence classes, including anti hypertensive drugs, ACE inhibitors, Betablockers, and calcium channel blockers. Despite multiple effective medication classes and numerous medicines into each class, high blood pressure (BP) management rates are poor. According to estimates, only around thirty-five of hypertensive individuals have both diastolicand systolic blood pressure management (Thoenes M.et. al.,2009), with same counts from United States (Chobanian AV et. al.2003) and other countries (Mori H et. al.2006). This loss of blood pressure management is not due to a lack of medication; according to one research, around thirty percent of medicated hypertensives use one hypertension medicine, forty percent take two fludrocortisone, and thirty percent take three or even more fludrocortisones (Rodriguez-Roca GC et. al. 2009). The findings show that the present trial-and-error methodology to bp therapy is ineffective, and that new methods for determining the best hypertensive strategy for a given individual are required. The genomic data, or functional genomics, application is to determine the best appropriate medicine for specific patient is major way for individualizing hypertension treatment. Considering the high health costs of hypertension and the low rates of blood pressure management, hypertension pharmacodynamics has a lot of promise. Epigenetics is concerned with genes, transcriptomes, and proteins. It have ability to improve patient care by enhancing illness detection and adopting patient-specific therapies. Molecular genetic pharmacogenetics was formerly centered on clinical studies. It is presently being expanded by applying genome-wide techniques to clarify the hereditary basis of variances in medication responsiveness across people.","PeriodicalId":7297,"journal":{"name":"Advanced Materials Proceedings","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Materials Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5185/amp.2022.010429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
These drugs are commonly used but, in some cases, they may become harmful for the person who is going through this medication so in this case pharmacogenomics of antihypertensive drugs are used. There are a variety of useful medication adherence classes, including anti hypertensive drugs, ACE inhibitors, Betablockers, and calcium channel blockers. Despite multiple effective medication classes and numerous medicines into each class, high blood pressure (BP) management rates are poor. According to estimates, only around thirty-five of hypertensive individuals have both diastolicand systolic blood pressure management (Thoenes M.et. al.,2009), with same counts from United States (Chobanian AV et. al.2003) and other countries (Mori H et. al.2006). This loss of blood pressure management is not due to a lack of medication; according to one research, around thirty percent of medicated hypertensives use one hypertension medicine, forty percent take two fludrocortisone, and thirty percent take three or even more fludrocortisones (Rodriguez-Roca GC et. al. 2009). The findings show that the present trial-and-error methodology to bp therapy is ineffective, and that new methods for determining the best hypertensive strategy for a given individual are required. The genomic data, or functional genomics, application is to determine the best appropriate medicine for specific patient is major way for individualizing hypertension treatment. Considering the high health costs of hypertension and the low rates of blood pressure management, hypertension pharmacodynamics has a lot of promise. Epigenetics is concerned with genes, transcriptomes, and proteins. It have ability to improve patient care by enhancing illness detection and adopting patient-specific therapies. Molecular genetic pharmacogenetics was formerly centered on clinical studies. It is presently being expanded by applying genome-wide techniques to clarify the hereditary basis of variances in medication responsiveness across people.
这些药物是常用的,但在某些情况下,它们可能对正在服用这种药物的人有害所以在这种情况下,使用抗高血压药物的药物基因组学。有多种有用的药物依从性,包括抗高血压药物,ACE抑制剂,β受体阻滞剂和钙通道阻滞剂。尽管有多种有效的药物类别,并且每个类别中有许多药物,但高血压(BP)的治愈率很低。据估计,只有大约35名高血压患者同时进行舒张压和收缩压管理(Thoenes M.et)。al.,2009),同样的数据来自美国(Chobanian AV et. al.2003)和其他国家(Mori H . et. al.2006)。失去对血压的控制并不是因为缺乏药物治疗;根据一项研究,大约30%的高血压药物患者使用一种高血压药物,40%服用两种氟化可的松,30%服用三种甚至更多的氟化可的松(Rodriguez-Roca GC et al. 2009)。研究结果表明,目前的试错方法对血压治疗是无效的,需要新的方法来确定特定个体的最佳高血压治疗策略。将基因组数据或功能基因组学应用于确定最适合特定患者的药物是个体化高血压治疗的主要途径。考虑到高血压的高健康成本和低血压管理率,高血压药效学有很大的希望。表观遗传学涉及基因、转录组和蛋白质。它有能力通过加强疾病检测和采用患者特异性治疗来改善患者护理。分子遗传药物遗传学以前以临床研究为中心。目前正在通过应用全基因组技术来阐明人与人之间药物反应差异的遗传基础,从而扩大这项研究。